News & Updates

Treatment with the nonsteroidal topical cream tapinarof 1% for up to 52 weeks helps control plaque psoriasis in the phase III PSOARING 3 trial.

Treatment with the combination of vancomycin and piperacillin/tazobactam (VAN + PTZ) appears to be associated with a greater prevalence of acute kidney injury as compared with VAN or PTZ monotherapy or with the concurrent use of VAN and cefepime or carbapenem, a study reports.

The oral selective JAK*1 inhibitor abrocitinib is superior to dupilumab for relieving itch and achieving skin clearance in people with moderate-to-severe atopic dermatitis (AD), according to results from a head-to-head comparison in the JADE DARE trial presented at EADV 2021.

Opioid fills are common among women who have undergone hysterectomy, and those with preoperative anxiety and depression are more prone to persistent use and related complications, according to a study.

New drug applications approved by US FDA as of 01-15 October 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.